User profiles for PA Brogan

Paul Brogan

University College London
Verified email at ucl.ac.uk
Cited by 15328

Management of Kawasaki disease

…, D Shingadia, R Tulloh, NJ Klein, PA Brogan - Archives of disease in …, 2014 - adc.bmj.com
Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with
vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. In …

Classification criteria for autoinflammatory recurrent fevers

…, K Barron, E Ben-Cherit, PA Brogan… - Annals of the …, 2019 - ard.bmj.com
Background Different diagnostic and classification criteria are available for hereditary
recurrent fevers (HRF)—familial Mediterranean fever (FMF), tumour necrosis factor receptor-…

Recommendations for the management of autoinflammatory diseases

…, J Anton, KS Barron, PA Brogan… - Annals of the …, 2015 - ard.bmj.com
<p>Autoinflammatory diseases are characterised by fever and systemic inflammation, with
potentially serious complications. Owing to the rarity of these diseases, evidence-based …

Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature

…, CA Bacino, R Battini, E Bertini, PA Brogan… - Nature …, 2012 - nature.com
Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of
adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the …

[HTML][HTML] JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

…, S Ozen, PG Wakim, PA Brogan… - The Journal of …, 2018 - Am Soc Clin Investig
BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy with
systemic inflammation, an IFN response gene signature, inflammatory organ damage, and …

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

…, E Andersen, MR Eyre, D Eleftheriou, PA Brogan… - Neurology, 2014 - AAN Enterprises
… of Pittsburgh (GA), University of Pittsburgh, PA; Hacettepe University Child Neurology (BA), …
Brogan, PhD … Brogan has received consultancy fees from Roche and Novartis. R. Kneen, G. …

Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research

PA Brogan, A Bose, D Burgner, D Shingadia… - Archives of disease in …, 2002 - adc.bmj.com
This article proposes a clinical guideline for the diagnosis and treatment of Kawasaki disease
in the UK based on the best available evidence to date, and highlights areas of practice …

The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international …

…, S Ozen, R Cimaz, A Jansson, PA Brogan… - Annals of the …, 2014 - ard.bmj.com
Objective To evaluate the genetic findings, demographic features and clinical presentation
of tumour necrosis factor receptor-associated autoinflammatory syndrome (TRAPS) in …

Endothelial and platelet microparticles in vasculitis of the young

PA Brogan, V Shah, C Brachet, A Harnden… - Arthritis & …, 2004 - Wiley Online Library
Objective Microparticles are released from endothelial cells in response to a variety of
injurious stimuli and recently have been shown to be increased in a number of diseases …

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

…, RP Naden, JWJ Bijlsma, PA Brogan… - Annals of the …, 2017 - ard.bmj.com
Objectives To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-related
morbidity and GC-sparing ability of other therapies. Methods Nineteen experts on GC …